Figure 11.

Cytokine profile in serum of patients. The line chart shows the median fluorescent intensity values (group means and 95% confidence limits calculated on the logarithmic scale) of 65 cytokines for controls (at baseline [base]) and for patients with DAOSD and patients without it (at baseline [base], after 1 month [1m] and after 4 months [4m]). All P values were false discovery rate corrected for testing 65 cytokines. P values < 0.05 were considered statistically significant. The figure shows the details of cytokines with a significant group effect. A Wilcoxon test compared the controls with the patients receiving dupilumab at baseline (CoT1). AD = atopic dermatitis; DAOSD = dupilumab–associated ocular surface disease; G = group effect; IL = interleukin; T = time effect; X = time interaction effect; APRIL = a proliferation-inducing ligand; BAFF = B cell activating factor; BLC = B lymphocyte chemoattractant; CD30 = cluster of differentiation 30; CD40L = cluster of differentiation 40 ligand; ENA-78 = epithelial neutrophil-activating protein 78; FGF-2 = fibroblast growth factor 2; G-CSF = granulocyte colony-stimulating factor; GM-CSF = granulocyte-macrophage colony stimulating factor; GRO-alpha = CXCL1 = C-X-C motif chemokine ligand 1; HGF = hepatocyte growth factor; I-TAC = interferon-inducible T cell alpha chemoattractant; IFN = interferon; LIF = leukemia inhibitory factor; M-CSF = macrophage colony-stimulating factor; MCP = monocyte chemoattractant protein; MDC = macrophage-derived chemokine; MIF = macrophage migration inhibitory factor; MIG = monokine induced by gamma-interferon = CXC ligand 9; MIP = macrophage inflammatory protein; MMP = matrix metalloproteinase; NGF = nerve growth factor; SCF = stem cell factor; SDF = stromal cell-derived factor = CXCL12; TNF = tumor necrosis factor; TRAIL = tumor necrosis factor related apoptosis inducing ligand; TSLP = thymic stromal lymphopoietin; TWEAK = tumor necrosis factor-like weak inducer of apoptosis.